Repinotan

DB06506InvestigationalSmall molecule

Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

Mechanism: Repinotan is a 5-HT1A receptor agonist which inhibits glutamate induced depolarization. The effect of repinotan in neuronal cells has been reported to be mediated by a variety of mechanisms/signaling pathways, including activation of the anti-apoptotic phosphatidylinositol 3-kinase (PI-3K) pathway, inhibition of glutamate release (probably via opening of K+ channels leading to membrane hyperpolarization), extracellular-regulated kinase (Erk)-stimulated Bcl-2 expression or inhibition of caspase-3 activity, and increased release of the neurite extension factor S-100 beta.
Curator reviewed
Primary indication: Investigated for use/treatment in strokes, cerebral ischemia, and depression.Curator reviewed
Formula / weight: C₂₁H₂₄N₂O₄S · 400.49 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyYGYBFMRFXNDIPO-QGZVFWFLSA-NSMILESO=C1N(CCCCNC[C@H]2CCC3=CC=CC=C3O2)S(=O)(=O)C2=CC=CC=C12

Targets

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

354Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Repinotan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.